Non-fucosylated Anti-Human IL23 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ14] (CAT#: BioBet-014ZP) Datasheet

Whole Humanized Antibody
ADCC-enhanced Tildrakizumab is a non-fucosylated anti-IL23 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-IL23 Tildrakizumab, a biobetter by reducing fucosylation of the Fc region of Tildrakizumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Moderate-severe plaque psoriasis
Therapeutic antibody; biobetter
Not Available

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Tildrakizumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Full Name
interleukin 23 subunit alpha
This gene encodes a subunit of the heterodimeric cytokine interleukin 23 (IL23). IL23 is composed of this protein and the p40 subunit of interleukin 12 (IL12B). The receptor of IL23 is formed by the beta 1 subunit of IL12 (IL12RB1) and an IL23 specific subunit, IL23R. Both IL23 and IL12 can activate the transcription activator STAT4, and stimulate the production of interferon-gamma (IFNG). In contrast to IL12, which acts mainly on naive CD4(+) T cells, IL23 preferentially acts on memory CD4(+) T cells.
Alternative Names
P19; SGRF; IL-23; IL-23A; IL23P19
Gene ID
UniProt ID
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL23A include Multiple Sclerosis and Inflammatory Bowel Disease.
Related Pathways
Its related pathways are Tuberculosis and PEDF Induced Signaling.
Combined with IL12B to form IL-23 interleukin, which is a heterodimeric cytokine that plays a role in innate immunity and adaptive immunity. IL-23 and IL-17 may constitute an acute response to surrounding tissue infection. IL-23 binds to the heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory instead of naive T cells, and promotes the production of pro-inflammatory cytokines. IL-23 induces autoimmune inflammation, so it may be the cause of autoimmune inflammatory diseases and may be important for tumor occurrence.
Post-translational modifications
No Post-translational modifications
Trade name
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
CAS number
Antibody Isotype
Whole Humanized Antibody
Antibody Clone
Tildrakizumab is a humanized IgG1κ antibody designed to treat monoclonal antibodies against immune-mediated inflammatory diseases. The US Food and Drug Administration (FDA) approved Tildrakizumab for the treatment of moderate to severe plaque psoriasis in 2018.
Moderate-severe plaque psoriasis

IL-23 is a naturally occurring cytokine involved in inflammation and immune responses. Studies have shown that targeting IL-23p19 alone is a promising method for treating patients with moderate to severe chronic plaque psoriasis.
Tildrakizumab is a humanized IgG1κ antibody used to block interleukin-23. The drug selectively binds to the IL-23 p19 subunit and neutralizes its function. IL-23 regulates Th17 cells and is a potent activator of keratinocyte proliferation. Tildrakizumab inhibits the release of pro-inflammatory cytokines and chemokine tags.
As tildrakizumab is an IgG1 antibody, it has the potential to induce ADCC and / or CDC.
Autoimmune diseases
Moderate-severe plaque psoriasis

All products and services are for Research Use Only. Do Not use in humans.


Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *